"Yike" project phase III clinical trial research progress release

Recently, Wen Yumei, an academician of the Chinese Academy of Sciences, published a paper in the Journal of Hepatology, showing that the therapeutic vaccine - phase III clinical trial of "Yike" project found that when the number of vaccinations increased from 6 to 12, the effectiveness decreased In 2011, Huali family acquired Haitai Investment Co., Ltd and participated in the "Yike" project Together with Guangzhou Pharmaceutical and Chongqing beer, Huali family became three listed enterprises involved in the research and development of therapeutic hepatitis B vaccine The paper showed that the phase III trial increased to 12 doses based on the previous phase IIB clinical trial using 6 doses of vaccine However, compared with the results of phase IIB trial, the HBeAg seroconversion rate of phase III therapeutic vaccine group decreased from 21.8% to 14.0%, while that of placebo group increased from 9% to 21.9% The conclusion is that over stimulation with therapeutic vaccine will lead to the decrease of effectiveness According to the schedule disclosed when Huali family acquired Haitai investment, "Yike" project should release phase III clinical report as early as 2011, and obtain the "new drug certificate" and "drug production license" this year The clinical data of the project has not been released yet Many people in the vaccine research and development field have told wisdom that the research and development of "Yike" is not optimistic and may have failed At present, "YIG" is the only therapeutic hepatitis B vaccine that has entered the phase III sprint in China Before Chongqing beer black swan, the market has been cautious in measuring "YIG" According to Wen Yumei's paper published in the Journal of Hepatology this time, the phase III trial of "Yike" project in 450 patients has not failed, but the progress cannot define the prospect of "Yike" The therapeutic vaccine of Guangzhou Pharmaceutical industry is still in the IIb clinical trial stage, and will be unblinded this year The result of Unblinding determines the success of vaccine research; another Chongqing beer, which has developed the therapeutic hepatitis B vaccine, has already had the vaccine dream broken Related reading Chongqing beer hepatitis B vaccine has no significant effect At the beginning of the trial, it once fell to a halt Http://www.bioon.com/industry/finance/521413.shtml, the concept of hepatitis B vaccine, singing the super Bull Stock, Chongqing beer, http://www.bioon.com/industry/finance/512329.shtml, the trial of hepatitis B vaccine in Chongqing beer, playing Taiji, http://www.bioon.com/industry/finance/520695.shtml, declaring war on hepatitis B: salvation of a big country Http://www.bioon.com/biology/sars/312930.shtml the protective effect of hepatitis B vaccine can last for 20 years http://www.bioon.com/industry/mdnews/454989.shtml